QUANTITATIVE BONE SCINTIGRAPHY: A methodological evaluation in prostate cancer

References

• BOLTON D. M.: Detection of relapsed disease — is prostate-specific antigen enough? In: Questions and uncertainties about prostate cancer, p. 255. Edited by W B. Peeling. Blackwell Science, Oxford 1996.
   Google Scholar
• BUSHNELL D. L., KAHN D., HUSTON B. et al.: Utility of SPECT imaging for determination of vertebral metastases in patients with known primary tumors. Skeletal Radiol. 24 (1995), 13.
   PubMed Web of Science ®Google Scholar
• CONDON B. R., BUCHANAN R., GARVE N. W. et al.: Assess-ment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging. Br. J. Radiol. 54 (1981), 18.
   PubMed Web of Science ®Google Scholar
• CORRIE D., TIMMONS J. H., BAUMAN J. M. et al.: Efficacy of follow-up bone scans in carcinoma of the prostate. Can-cer 61 (1988), 2453.
   Google Scholar
• ERDI Y. E., Humm J. L., IMBRIACO M. et al.: Quantitative bone metastases analysis based on image segmentation. J. Nucl. Med. 38 (1997), 1401.
   Google Scholar
• FIGG W. D., AMMERMAN K., PATRONAS N. et al.: Lack of correlation between prostate-specific antigen and the pres-ence of measurable soft tissue metastases in hormonere-fractory prostate cancer. Cancer Invest. 14 (1996), 513.
   PubMed Web of Science ®Google Scholar
• FLEMING J. S.: A technique for the absolute measurement of activity using a gamma camera and computer. Phys. Med. Biol. 24 (1979), 176.
   PubMed Web of Science ®Google Scholar
• FRONT D., ISRAEL 0., JERUSHALMI J. et al.: Quantitative bone scintigraphy using SPECT. J. Nucl. Med. 30 (1989), 240.
   Google Scholar
• JACOBSSON A. E & FOGELMANN I.: Bone scanning in clinical oncology. Does it have a future? Eur. J. Nucl. Med. 25 (1998), 1219.
   Google Scholar
• MODONI S., CALO E., NARDELLA G. et al.: PSA and bone scintigraphy. Int. J. Biol. Markers 12 (1997), 158.
   PubMed Web of Science ®Google Scholar
• OESTERLING J. E.: Using prostate-specific antigen to elimin-ate unnecessary diagnostic tests. Significant world-wide economic implications. Urology 46 (1995), Suppl. A, p. 26.
   Google Scholar
• OSMOND J. D. III, PENDERGRASS H. P & POTSAID M. S.: Accuracy of 99mTc-diphosphonate bone scans and rontgen-ograms in the detection of prostate, breast and lung carci-noma metastases. AJR 125 (1975), 972.
   Google Scholar
• PARKER D. & HART G. C.: Improved sensitivity in bone scintigraphy using quantitative spinal profile analysis. Nucl. Med. Commun. 9 (1988), 631.
   PubMed Web of Science ®Google Scholar
• PARTIN A. W & OESTERLING J. E.: The clinical usefulness of prostate specific antigen. Update. J. Urol. 152 ( 1994), 1358.
   Google Scholar
• POLLEN J. J. & SHLAER W. J.: Osteoblastic response to suc-cessful treatment of metastatic cancer of the prostate. AJR 132 (1979), 927.
   Google Scholar
• RYDH A., ToAnc R., TAVELIN B. et al.: The predictive value of prostate-specific antigen (PSA), tumour stage (T) and tumour grade (G) for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand. J. Urol. Nephrol. 33 (1999), 89.
   Google Scholar
• SLACK N. H., KARR J. P, CHu T. M. et al.: An assessment of bone scans for monitoring osseous metastases in pa-tients being treated for prostate carcinoma. Prostate 1 (1980), 259.
   Google Scholar
• SOLOWAY M. S., HARDEMAN S. W, MICKEY D. et al.: Strati-fication of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988), 195.
   PubMed Web of Science ®Google Scholar
• SUNDKVIST G. M. G., AHLGREN L., LILJA B. et al.: Re-peated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchidectomy. Eur. J. Nucl. Med. 14 (1988), 2036.
   Google Scholar
• VAN DER WALL H.: The evaluation of malignancy. Meta-static bone disease. In: Nuclear medicine in clinical diag-nosis and treatment, p. 949. Edited by I. P. C. Murray & P. J. Ell. Churchill Livingstone, London 1994.
   Google Scholar
• VAN RENSBURG A. J., ALBERTS A. S. & Louw W. K. A.: Quantifying the radiation dosage to individual skeletal lesions treated with samarium- 153-EDTMP. J. Nucl. Med. 39 (1998), 2110.
   Google Scholar